GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (LTS:0VRQ) » Definitions » 12-1 Month Momentum %

CRISPR Therapeutics AG (LTS:0VRQ) 12-1 Month Momentum % : -4.96% (As of May. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is CRISPR Therapeutics AG 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-15), CRISPR Therapeutics AG's 12-1 Month Momentum % is -4.96%.

The industry rank for CRISPR Therapeutics AG's 12-1 Month Momentum % or its related term are showing as below:

LTS:0VRQ's 12-1 Month Momentum % is ranked better than
64.25% of 1488 companies
in the Biotechnology industry
Industry Median: -22.915 vs LTS:0VRQ: -4.96

Competitive Comparison of CRISPR Therapeutics AG's 12-1 Month Momentum %

For the Biotechnology subindustry, CRISPR Therapeutics AG's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's 12-1 Month Momentum % falls into.



CRISPR Therapeutics AG  (LTS:0VRQ) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CRISPR Therapeutics AG  (LTS:0VRQ) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


CRISPR Therapeutics AG 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG (LTS:0VRQ) Business Description

Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

CRISPR Therapeutics AG (LTS:0VRQ) Headlines

No Headlines